Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of July 7, 2026, KLRS trades at $4.68 with a market cap of $113.01M and a P/E ratio of 0.00. KLRS moved -2.95% today. Year to date, KLRS is -44.51%; over the trailing twelve months it is +86.00%. Its 52-week range spans $2.14 to $12.90. Analyst consensus is strong buy with an average price target of $18.67. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for KLRS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $4.68 |
| Market Cap | $113.01M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $2.14 |
| Volume | 48.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover KLRS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.67.